HealthHighlight

 NAFDAC approves Chloroquine mass production after clinical trials in China

260

 

For possible clinical trial treatment of COVID-19 patients, the National Agency for Food and Drug Administration and Control (NAFDAC) has approved mass production of emergency stockpile of Chloroquine.

NAFDAC Director-General, Prof. Mojisola Adeyeye, disclosed this in a statement in Abuja on Monday.

 

Chloroquine was reported to have demonstrated marked efficacy and acceptable safety in treating COVID-19 associated pneumonia in multi-centre clinical trials conducted in China.

The study, which involved 10 hospitals in Wuhan, Jingzhou, Guangzhou, Beijing, Shanghai, Chongqing and Ningbo, was reported to be superior to controlling pneumonia associated with COVID-19 and shortening the cause of the disease.

Nigeria discontinued the use of Chloroquine as an anti-malaria drug many years ago because of the resistance the parasite developed against the drug.

Adeyeye, however, said sourcing the raw material — Active Pharmaceutical Ingredient (API) chloroquine phosphate — could be difficult because its was discontinued in the country years ago.
“About four weeks ago, I approached a local drug manufacturing company in Nigeria (May and Baker), a member of Pharmaceutical Manufacturing Group of Manufacturing Association of Nigeria (PMGMAN), whose flagship product in the past was chloroquine, to make a batch of the drug for emergency stock.

“The company had NAFDAC approval for the production of the drug as antimalarial many years ago before the discontinuation. But my fear is possible difficulty in getting the API due to the fact that the drug has been discontinued long ago.

“But a few days after, they called that they were able to get the API, and I asked them to manufacture a batch for emergency stock just in case more people become exposed and infected with the virus.

“The batch has been manufactured and the company plans to make more batches if needed,” she said.

She warned Nigerians against using it without a medical doctor or clinician’s prescription for cases of clinical trial treatment of COVID-19.

 “It has side effects such as gastrointestinal upset, blurred vision, headache and pruritis (itching). The itching can be relieved by using antihistamine.
“Prolonged use can also cause retinopathy or vision impairment,” she warned.
The DG said the agency would ensure that the clinical trial protocol guidelines are followed.
“NAFDAC wishes the clinical research teams great success in stopping the raging pandemic.”

Leave a comment

Related Articles

19,000 children from 427 orphanage homes across Nigeria to benefit from Davido’s N300m largesse

In a significant move aimed at bolstering the welfare of vulnerable children...

Deceased Ondo Gov. Akeredolu interred in Owo amid pomp as Pres. Tinubu extols him

Ondo State Governor, Mr Oluwarotimi Odunayo Akeredolu, who died in office in...

Just In: Ex-NBA President, Olumide Akpata, emerges Edo LP guber candidate

Former President of the Nigerian Bar Association and Edo State governorship aspirant,...

Father drowns, rescuing his underage son, who falls into well

In a last-minute effort to save his son, who mistakenly fell into...

Tinubu names Gbenga Alade as AMCON MD/CEO

President Bola Tinubu has appointed a new management team for the Asset...

Port Harcourt refinery to start producing 2.2m litres of diesel, petrol daily soon – FG

The Federal Government has announced that the Port-Harcourt Refinery is gearing up...

ECOWAS faces most difficult challenges since its formation – Ejime

A public affairs analyst, Mr. Paul Ejime, has lamented that the Economic...

Economic hardship: Lagos Govt. employees except teachers to work three days a week – Sanwo-Olu

Civil servants from grade levels 1 to 14 will start working three...

Tinted glass permit: Police to train enforcement officers, ICT analysts on issuance

In a bid to improve national security and curb criminal activities facilitated...

Senate Confirms Cardoso, Yuguda, 10 Others As Chair, MPC Members

The Senate has confirmed the appointments of the governor of the Central...

Breaking: Nigeria’s GDP grew by 3.46% in Q4 2023 – NBS

The National Bureau of Statistics (NBS) has announced growth in Nigeria’s gross...

FG stops exportation of cooking gas to crash price

The Federal Government, in its bid to crash the price of cooking...

Ex-Brazilian star Dani Alves jailed four years for rape

Ex-Brazilian star Dani Alves has been sentenced to four and a half...

Economic hardship: Nigerian military warns against calls for coup

The Nigerian military authorities have issued a stern warning to those calling...

Just in: After 26-month self-exile, Yoruba nation activist, Sunday Igboho returns to Nigeria

Chief Sunday Adeyemo, also referred to as Sunday Igboho, a foremost Yoruba...

Just in: 86 people murdered daily in South Africa — Police Minister

At least 86 people are killed daily in South Africa, according to...

Appointment: Kemi Nandap is the new Comptroller-General of Nigeria Immigration Service

The Nigeria Immigration Service (NIS) has a new Comptroller-General. She is Deputy...

Just in: Labour Party’s National Chairman, Abure, Arrested

The National Chairman of the Labour Party (LP), Mr Julius Abure, has...

Economic hardship: FG set to restart direct cash transfers to 15m households

The Federal Government has concluded plans to restart direct cash transfers to...